Clinical and economic impact of 2nd line initiation of empagliflozin after metformin, as compared to 2nd line initiation of sulfonylurea after metformin in patients with type 2 diabetes and cardiovascular disease First published 27/10/2021 Last updated 23/04/2024 EU PAS number:EUPAS43815 Study Finalised